HOX Therapeutics Ltd is a spin-off from the University of Surrey Oncology Department to develop new therapeutics for cancer, based on the role of HOX genes in cancer.

Founded in 2013 by world-leading experts in the HOX family of genes’ role in cancer, Professor Hardev Pandha, Medical Oncologist, Head of Oncology, University of Surrey and Professor Richard Morgan, Molecular Oncologist, Institute of Cancer Therapeutics, Bradford. The foundation of the company is based on 15 years of research and publications.

The company has developed a novel treatment approach, focussing on inhibiting the HOX-PBX binding in a highly targeted manner resulting in the generation of new IP, wholly owned by the company.

Our technology